udibi

What udibi does

UDIBI (Unidad de Desarrollo e Investigación en Bioprocesos) is a biopharmaceutical research and development unit embedded within Mexico's Instituto Politécnico Nacional (IPN), operating through the Escuela Nacional de Ciencias Biológicas in Mexico City. The unit delivers a vertically integrated set of services spanning antibody discovery and engineering, protein design and expression, biological and cell-based assays, in vivo animal models with IVIS imaging, biopharmaceutical characterization (including LC-MS), authorized third-party analytical and biocomparability testing via its LIAT subsidiary, and regulatory support. UDIBI also licenses the proprietary GlobalBio Humanization Method (GBM) through a strategic relationship with GlobalBio Inc, enabling clients to reduce non-human residues in candidate antibodies and generate defensable IP. Its primary customers are pharmaceutical and biopharmaceutical companies requiring CRO support, supplemented by research institutions, universities, and healthcare and regulatory entities.

The commercial offering extends beyond services into a catalog of research-use products, including recombinant SARS-CoV-2 Spike-RBD proteins (Wuhan, Delta, Omicron variants), a portfolio of human neutralizing monoclonal IgG1 antibodies targeting SARS-CoV-2 RBD, TNF-alpha, lysozyme, and Chikungunya, and the registered UDITEST-V2G diagnostic kit. UDIBI also maintains a public R&D pipeline covering therapeutic antibodies, immunomodulators, CAR-T cell therapy, and a leukemia disease model, signaling intent to evolve from fee-for-service CRO work into proprietary therapeutic development.

Commercially, UDIBI runs a hybrid go-to-market: a direct-to-consumer e-commerce storefront with PayPal checkout, international shipping, and dual USD/MXN pricing for reagents and diagnostic kits, complemented by a field sales motion for CRO contracts, antibody engineering programs, and authorized laboratory testing, plus event-driven lead generation at BIO International Convention and Antibody Engineering & Therapeutics. The organization is wholly government-owned as part of IPN's public academic infrastructure, with no private equity or venture capital ownership identified, and no disclosed revenue, headcount, or funding data.

Name

udibi

Legal name

Unidad de Desarrollo e Investigación en Bioprocesos

Website

https://udibi.com.mx

Company type

Private

Operating status

Operating

Short description

UDIBI is a biopharmaceutical R&D unit within Mexico's Instituto Politécnico Nacional offering antibody engineering, protein expression, in vivo animal models, authorized analytical testing, and biopharmaceutical characterization services and research-use reagents to pharma, biotech, academic, and regulatory clients.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Testing Laboratories and Services (541380)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

DMPK / ADME & Bioanalysis (HLAGAFAC), Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA)

Keywords

• Biopharmaceutical research
• Contract research services
• Antibody engineering
• Preclinical studies
• Analytical testing

Headquarters

HQ city

Ciudad de México (Mexico City)

HQ country

Mexico

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Products Sales: Sale of recombinant proteins, antibodies, and diagnostic kits for research use (RUO). Products include SARS-CoV-2 antigens, neutralizing antibodies against various targets, and the UDITEST-V2G diagnostic kit
2. Contract Research Services: CRO services including animal research models, biological essays, cell-based assays, and preclinical testing for pharmaceutical clients
3. Antibody Engineering Services: Custom antibody services including discovery, optimization, humanization, and characterization for therapeutic development
4. Regulatory and Testing Services: Authorized third-party laboratory testing, biocomparability testing, and regulatory support for product approval

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

UDIBI is a contract research and bioprocess development unit that sells antibody discovery/engineering services, preclinical animal research with in vivo imaging, biopharmaceutical characterization, and authorized analytical testing for pharmaceutical clients. It also produces and sells recombinant proteins, human neutralizing monoclonal antibodies, and the UDITEST-V2G diagnostic kit via its online shop for research use.

Product overview

UDIBI (Unidad de Desarrollo e Investigación en Bioprocesos) is a research and development unit affiliated with the Instituto Politécnico Nacional (IPN) through the Escuela Nacional de Ciencias Biológicas. The company offers a portfolio of recombinant proteins (including SARS-CoV-2 Spike RBD variants from Wuhan, Delta, and Omicron strains) and human neutralizing monoclonal antibodies for research use, along with antibody discovery, development, and humanization services using the proprietary GlobalBio Humanization Method (GBM). The service portfolio includes CRO services for animal research models (pharmacodynamics, in vivo imaging IVIS, infectious and immune disease models), biological testing services (cell-based assays, physicochemical and biological control), analytical laboratory services (authorized testing laboratory, biocomparability testing), regulatory support, biopharmaceutical characterization, and protein design/expression services. The company also develops a pipeline of therapeutic antibodies, immunomodulators, and CAR-T cell therapies, and offers the UDITEST-V2G® diagnostic kit for COVID-19 detection. The products are sold primarily for research use only (RUO), with services targeted at pharmaceutical and biotech companies, research institutions, and healthcare organizations.

Differentiator

Problem solved

Functional benefit

Products and services

• SARS-CoV-2 Recombinant Proteins (Spike RBD Wuhan, Delta, Omicron variants) Recombinant SARS-CoV-2 Spike-RBD proteins from the wildtype (Wuhan), Delta (B.1617.2) and Omicron (B.1.1.529) strains with HIS tag, sold for research applications to laboratories and academic researchers.
• Human Neutralizing Monoclonal Antibodies (Anti-Chikungunya, Anti-TNF-alpha, Anti-SARS-CoV-2 RBD) Catalog of human neutralizing IgG1 monoclonal antibodies targeting Chikungunya virus, TNF-alpha, and SARS-CoV-2 RBD (Wuhan, Delta, Omicron variants) with characterized affinities (KD values from <100 pM to 27 nM), sold for research use only to academic and industry researchers.
• UDITEST-V2G Diagnostic Kit Registered diagnostic kit for detecting SARS-CoV-2 antibodies, part of UDIBI's COVID-19 solutions portfolio, sold to laboratories and healthcare institutions.
• Biological / Cell-Based Assays Laboratory services for biological testing including cell-based assays used to evaluate therapeutic candidates, targeted at pharmaceutical and biotech companies developing biologics.
• Animal Research Models (Preclinical CRO Services) Preclinical CRO services including primary pharmacodynamics, in vivo imaging with IVIS, infectious disease models, immunological disease models, neutropenic models, tumor inhibition studies, and in vivo toxicity testing for pharmaceutical and biotech clients.
• Antibody Engineering Services Custom antibody services including discovery and library development, optimization, and humanization using the proprietary GlobalBio Humanization Method (GBM) for therapeutic development clients.
• Authorized Analytical Testing Laboratory (CCAyAC) Services Authorized analytical testing laboratory services delivered through wholly-owned subsidiary LIAT, providing third-party physicochemical control, biological control, and microbiological control testing meeting regulatory compliance standards for pharmaceutical and biopharmaceutical clients.
• Regulatory Support Services Regulatory consulting and support services for pharmaceutical product development and approval processes, including biocomparability testing support for biosimilar submissions.
• Biopharmaceutical Characterization Services Services for characterizing biopharmaceutical products including physicochemical and biological analysis to support drug development and regulatory submissions.
• Protein Design and Expression Services Specialized protein design and expression services supporting recombinant protein production for research and development applications.
• Liquid Chromatography-Mass Spectrometry (LC-MS) Services Analytical services using LC-MS technology for protein and small molecule characterization supporting biopharmaceutical development.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• GlobalBio InccoreStrategic or Co-development PartnerStrategic partnership for antibody humanization services. GlobalBio Inc provides access to the GlobalBio Humanization Method (GBM), an innovative proprietary method for antibody humanization that minimizes non-human amino acid residues to improve molecule properties and generate intellectual property for clients.
• LIAT (Laboratorio Integral Analítico de Terceros)coreTechnology or IntegrationThird-party analytical laboratory partnership providing authorized analytical testing services including physicochemical control, biological control, and microbiological control testing. LIAT is presented as part of UDIBI's service ecosystem.
• Instituto Politécnico Nacional (IPN)coreStrategic or Co-development PartnerUDIBI is a unit within IPN's Escuela Nacional de Ciencias Biológicas and the Unidad de Investigación, Desarrollo e Innovación Médica y Biotecnológica. This institutional relationship provides access to academic talent, research infrastructure, and regulatory credibility.
• Escuela Nacional de Ciencias Biológicas (ENCB)coreStrategic or Co-development PartnerHost institution within IPN providing laboratory facilities, academic resources, and student talent pipeline for UDIBI's research and development operations.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• GenScript ProBio: Provides antibody development, protein expression, and biopharma CDMO services. Directly comparable to UDIBI's antibody engineering, protein design/expression, and biopharmaceutical characterization offerings.
• AbCellera Biologics: Antibody discovery and engineering platform using proprietary library and screening technologies. Comparable to UDIBI's antibody discovery, optimization, and humanization services for therapeutic applications.
• Bio-Techne: Global provider of recombinant proteins, antibodies, and immunoassay reagents for research use. Comparable to UDIBI's RUO antibody and protein SKUs (e.g., SARS-CoV-2 antigens, neutralizing antibodies).
• GlobalBio Inc: Strategic partner that provides the GlobalBio Humanization Method (GBM) used by UDIBI for antibody humanization services. Directly comparable as a specialist antibody engineering platform serving therapeutic development clients.
• ProteoGenix: Specialist in antibody production, humanization, and recombinant protein services. Closely comparable to UDIBI's antibody engineering and recombinant protein catalog for research use.

Broad incumbents

• Lonza Group: Global CDMO and bioprocess services provider. Comparable to UDIBI's protein expression, bioprocess, and characterization capabilities, but at incumbent scale with worldwide manufacturing footprint.
• WuXi Biologics: Global CRDMO offering antibody discovery, cell line development, and bioanalytical services. Operates broadly across the same biopharma services value chain as UDIBI but with vastly greater scale and international reach.
• Charles River Laboratories: Major global CRO offering preclinical services, animal models, and biologics testing. Comparable to UDIBI's preclinical animal research models and biopharmaceutical characterization services, but at much larger scale and global footprint.
• LakePharma (now Curia): Preclinical CRO offering antibody engineering, protein expression, and animal model services. Comparable to UDIBI's antibody services and animal research models, now operating within larger Curia CDMO platform.

Emerging players

• LIAT (Laboratorio Integral Analítico de Terceros): Authorized Mexican analytical testing laboratory and core subsidiary/partner of UDIBI providing physicochemical, biological, and microbiological control testing. Comparable niche overlap in authorized analytical testing for biopharmaceuticals within Mexico.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCxm9rny0WDaDSPIRswWbctw
• Facebookfacebook.com/udibiipn
• LinkedInlinkedin.com/company/udibi
• Instagraminstagram.com/udibi_mx

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about udibi